Immunogenic hyperthyroidism iodine-131-therapy of non-imunogenic, autonomous thyroid nodules: Results of a multicenter evaluation;Auftreten einer immunogene hyperthyreose nach radioiod-therapie fokaler schilddrusenautonomien

Medizinische Klinik

Volumn 94, Issue 5, 1999, Pages 239-244

  Weiss, Mayo ^a   Görges, Reiner ^b   Hirsch, Christine ^c   Bader, Jochen ^d   Tatsch, Klaus ^a   Hahn, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Focal thyroid nodule; Immunogenic hyperthyroidism; Iodine 131 therapy

Indexed keywords

IODINE 131; PERTECHNETIC ACID TC 99M; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AGED; ARTICLE; HUMAN; HYPERTHYROIDISM; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RADIOISOTOPE THERAPY; THYROID NODULE; THYROID SCINTISCANNING;

EID: 0344867032     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03045047     Document Type: Article

References (16)

1. Berglund J, Christensen SB, Hallengren B. Total and age-specific incidence of Graves' thyrotoxicosis, toxic nodular goitre and solitary toxic adenoma in Malmo. J Intern Med (GB) 1990;227:137-41.
2. Boddenberg B. Voth E. Schizha H. Immunogene Hyperthyreose nach Radioiod-Ab ation einer fokalen Autonomie. Nuklearmedizin 1993;32:18-22.
3. Charkes D. Graves' disease with functioning nodules (Marine-Lenhardt-Syndrome). J Nucl Med 1972;13:885-92.
4. Chiovato I, Santini F, Vitti P, et al. Appearance of thyroid stimulating anti-body and Graves' disease after Radioiodine therapy for toxic nodular goitre. Clin Endocrinol Oxf. 1994;40:8036.
5. Dunkelmann S, Rudolph F, Prillwitz A, et al. Schümichen C. Paradoxe Effekte der Radioid-Therapie bei funktioneller Schilddrüsenautonomie und milder Inmunthyreopathie. Nuklearmedizin 1998;37:17-22.
6. Furszyfer J, Kurland LT, McConahey WM, et al Graves disease in Olmsted County, Minnesota, 1935 through 1967. Mayo Clin Proc. 1970;45(9):636-44
7. Greenwald I. Studies of exophthalmic goiter. The course of mortality from exopthalmic goiter in Great Britain, 1919-1964. J Chronic Dis. 1968;21(7):483-91.
8. Hirsch C, Langhammer HR, Spyra I, et al. Incidence of immunogenic thyroid disease following treatment of plummer's disease with Iodine-131-therapy. Eur J Nucl Med 1995;22:799.
9. Nygaard B, Faber J, Veje A, et al. Appearance of Graves' disease after Radioiodine therapy for toxic as well as non-toxic multinodular goiture. Clin Endocrinol Oxf. 1995;43:129-30.
10. Paschke R, Vogg M, Swillens S, Correlation of microsomal antibodies with the intensity of the intrathyroidal autoimmune process in Graves' disease. J Clin Endocrinol Metab 1993;77:939-43
11. Reiners C. Radioiodine treatment of Basedow's disease: Interference and influence factors, risk estimation. Exp Clin Endocrinol Leipzig 1991; 97: 275-85.
12. Reiners C, Sieper I, Simins G. Schilddrüsendiagnostik -Diagnose und Therapiekontrolle, Behring 1994; Kap. 6, 47 bzw. 78.
13. Scherbaum WA, Paschke R. Bedentung der Schilddrüsenantikörper für Diagnostik und Verlaufsbeurteilung von Schilddrüsenerkrankungen. Internist 1995;36:303-9.
14. Vreden A, Kinser J, Rösler H, et al. Immunogene Hyperthyreose als Komplikation nach Radioiod-Therapie der nicht-immunogenen Hyperthyreose. Nuklearmedizin 1992;31:A24.
15. Weiss M, Mann K, Tatsch K, et al. Auftreten immunogener Hyperthyreosen nach Radioiod-Therapie von Schilddrüsenautonomien. Nuklearmedizin 1994;33:A43.
16. Weiss M, Görges R, Hirsch C, et al. Hahn K. Immunogene Hyperthyreose nach Radioiod-Therapie? Nuklearmedizin 1996;35:A 22.